New York—The era of direct-acting antiviral (DAA) therapy has brought cures for hepatitis C virus to hundreds of thousands of people. But some populations still are missing out on HCV therapy entirely or experiencing gaps in care that can render this costly treatment ineffective.
These gaps are particularly true in the treatment of incarcerated individuals, who have a much higher burden of HCV than the general population and are often unaware of their disease.
“The prevalence of